Search Results - "Renschler, Markus F."

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial by SOCINSKI, Mark A, BONDARENKO, Igor, IGLESIAS, Jose L, RENSCHLER, Markus F, KARASEVA, Nina A, MAKHSON, Anatoly M, VYNNYCHENKO, Igor, OKAMOTO, Isamu, HON, Jeremy K, HIRSH, Vera, BHAR, Paul, HUI ZHANG

“…This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel…”
Get full text

The emerging role of reactive oxygen species in cancer therapy by Renschler, Markus F

“…The generation of reactive oxygen species (ROS) can be exploited therapeutically in the treatment of cancer. One of the first drugs to be developed that…”
Get full text

Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy by JOTTE, Robert, CONKLING, Paul, REYNOLDS, Craig, GALSKY, Matthew D, KLEIN, Leonard, FITZGIBBONS, James F, MCNALLY, Richard, RENSCHLER, Markus F, OLIVER, Jennifer W

“…This phase II study evaluated the safety and efficacy of single-agent amrubicin versus topotecan in patients with small-cell lung cancer (SCLC) sensitive to…”
Get full text

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer by ETTINGER, David S, JOTTE, Robert, SALGIA, Ravi, MCNALLY, Richard, RENSCHLER, Markus F, OLIVER, Jennifer W, LORIGAN, Paul, GUPTA, Vicram, GARBO, Lawrence, ALEMANY, Carlos, CONKLING, Paul, SPIGEL, David R, DUDEK, Arkadiusz Z, SHAH, Chirag

“…Amrubicin is a synthetic anthracycline with potent topoisomerase II inhibition. This phase II study was conducted to confirm safety and activity of amrubicin…”
Get full text

Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial by Mehta, Minesh P., M.D, Shapiro, William R., M.D, Phan, See C., M.D, Gervais, Radj, M.D, Carrie, Christian, M.D, Chabot, Pierre, M.D, Patchell, Roy A., M.D, Glantz, Michael J., M.D, Recht, Lawrence, M.D, Langer, Corey, M.D, Sur, Ranjan K., M.D., Ph.D, Roa, Wilson H., M.D, Mahe, Marc A., M.D, Fortin, Andre, M.D, Nieder, Carsten, M.D, Meyers, Christina A., Ph.D, Smith, Jennifer A., Ph.D, Miller, Richard A., M.D, Renschler, Markus F., M.D

“…Purpose To determine the efficacy of motexafin gadolinium (MGd) in combination with whole brain radiotherapy (WBRT) for the treatment of brain metastases from…”
Get full text

Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial by MEYERS, Christina A, SMITH, Jennifer A, SIEMERS, Ross, CARRIE, Christian, GASPAR, Laurie E, CURRAN, Walter, PHAN, See-Chun, MILLER, Richard A, RENSCHLER, Markus F, BEZJAK, Andrea, MEHTA, Minesh P, LIEBMANN, James, ILLIDGE, Tim, KUNKLER, Lan, CAUDRELIER, Jean-Michel, EISENBERG, Peter D, MEERWALDT, Jacobus

“…To report the neurocognitive findings in a phase III randomized trial evaluating survival and neurologic and neurocognitive function in patients with brain…”
Get full text

Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases by MEHTA, Minesh P, RODRIGUS, Patrick, SCHULTZ, Christopher, TIMMERMAN, Robert, CURRAN, Walter, SMITH, Jennifer, PHAN, See-Chun, MILLER, Richard A, RENSCHLER, Markus F, TERHAARD, C. H. J, RAO, Aroor, SUH, John, ROA, Wilson, SOUHAMI, Luis, BEZJAK, Andrea, LEIBENHAUT, Mark, KOMAKI, Ritsuko

“…This phase III randomized trial evaluated survival as well as neurologic and neurocognitive function in patients with brain metastases from solid tumors…”
Get full text

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine by Von Hoff, Daniel D, Ervin, Thomas, Arena, Francis P, Chiorean, E. Gabriela, Infante, Jeffrey, Moore, Malcolm, Seay, Thomas, Tjulandin, Sergei A, Ma, Wen Wee, Saleh, Mansoor N, Harris, Marion, Reni, Michele, Dowden, Scot, Laheru, Daniel, Bahary, Nathan, Ramanathan, Ramesh K, Tabernero, Josep, Hidalgo, Manuel, Goldstein, David, Van Cutsem, Eric, Wei, Xinyu, Iglesias, Jose, Renschler, Markus F

“…In this report, the addition of nab-paclitaxel to standard gemcitabine increased the response rate, progression-free survival, and overall survival among…”
Get full text

18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer by Korn, Ronald L., Von Hoff, Daniel D., Borad, Mitesh J., Renschler, Markus F., McGovern, Desmond, Curtis Bay, R., Ramanathan, Ramesh K.

“…Background Positron emission tomography (PET) is poised to become a useful imaging modality in staging and evaluating therapeutic responses in patients with…”
Get full text

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer by von Pawel, Joachim, Jotte, Robert, Spigel, David R, O'Brien, Mary E R, Socinski, Mark A, Mezger, Jörg, Steins, Martin, Bosquée, Léon, Bubis, Jeffrey, Nackaerts, Kristiaan, Trigo, José M, Clingan, Philip, Schütte, Wolfgang, Lorigan, Paul, Reck, Martin, Domine, Manuel, Shepherd, Frances A, Li, Shaoyi, Renschler, Markus F

“…Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in small-cell lung cancer (SCLC) in phase II…”
Get full text

Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients With Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End Points by MEHTA, Minesh P, SHAPIRO, William R, CURRAN, Walter, SEE PHAN, SMITH, Jennifer A, MILLER, Richard A, RENSCHLER, Markus F, GLANTZ, Michael J, PATCHELL, Roy A, WEITZNER, Michael A, MEYERS, Christina A, SCHULTZ, Christopher J, ROA, Wilson H, LEIBENHAUT, Mark, FORD, Judith

“…Motexafin gadolinium is a redox mediator that selectively targets tumor cells, is detectable by magnetic resonance imaging (MRI), and enhances the effect of…”
Get full text

Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain Metastases by CARDE, Patrice, TIMMERMAN, Robert, MEHTA, Minesh P, KOPROWSKI, Christopher D, FORD, Judith, TISHLER, Roy B, MILES, Dale, MILLER, Richard A, RENSCHLER, Markus F

“…Motexafin gadolinium is a magnetic resonance imaging (MRI)--detectable redox active drug that localizes selectively in tumor cells and enhances the effect of…”
Get full text

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study by Kunzmann, Volker, Ramanathan, Ramesh K, Goldstein, David, Liu, Helen, Ferrara, Stefano, Lu, Brian, Renschler, Markus F, Von Hoff, Daniel D

“…Results from the phase 3 Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) led to approval of nab-paclitaxel plus gemcitabine for first-line…”
Get full text

Weekly nab -Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes by Hirsh, Vera, Ko, Amy, Pilot, Richard, Renschler, Markus F, Socinski, Mark A

“…Micro-Abstract The association between diabetes and clinical outcomes in patients with advanced non–small-cell lung cancer (NSCLC) is unclear. Therapy with nab…”
Get full text

Weekly nab -Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment by Langer, Corey J, Hirsh, Vera, Ko, Amy, Renschler, Markus F, Socinski, Mark A

“…Micro-Abstract Treatment options are limited for patients with cancer and renal impairment. In a subset analysis of patients with advanced non–small-cell lung…”
Get full text

Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer by Hirsh, Vera, Okamoto, Isamu, Hon, Jeremy K, Page, Ray D, Orsini, James, Sakai, Hiroshi, Zhang, Hui, Renschler, Markus F, Socinski, Mark A

“…nab-Paclitaxel (nab-P) is approved, in the United States, in combination with carboplatin for the first-line treatment of advanced non-small-cell lung cancer,…”
Get more information

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial by Yardley, Denise A, Brufsky, Adam, Coleman, Robert E, Conte, Pierfranco F, Cortes, Javier, Glück, Stefan, Nabholtz, Jean-Mark A, O'Shaughnessy, Joyce, Beck, Robert M, Ko, Amy, Renschler, Markus F, Barton, Debora, Harbeck, Nadia

“…Triple-negative breast cancer is an aggressive disease with unmet clinical needs. In a phase III study of patients with metastatic triple-negative breast…”
Get full text

Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. “A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011 by Von Hoff, Daniel D, Renschler, Markus F

Get full text

A proposed approach for analyzing post-study therapy effect in survival analysis by Luo, Xiaolong, Li, Mingyu, Wu, Chengqing, Xu, Qiang, Chen, Guang, Dornseif, Bruce E., Renschler, Markus F., Koch, Gary

“…Clinical trials that explore long-term endpoints may confound the analysis when post-study therapy effects are considered. This article introduces a procedure…”
Get full text

Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial by Yardley, Denise A, Brufsky, Adam, Coleman, Robert E, Conte, Pierfranco F, Cortes, Javier, Glück, Stefan, Nabholtz, Jean-Mark A, O'Shaughnessy, Joyce, Beck, Robert M, Ko, Amy, Renschler, Markus F, Barton, Debora, Harbeck, Nadia

Get full text